Payment overview · 2025
General Payments
$318.78
19 reported records · 6 companies
Healthcare provider profile · identity verified
Allison S Thomas, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BATTLE CREEK, MI · NPI 1386687028
Verified facts
What the public records show
CMS Open Payments records show Allison S Thomas, M.D. received $318.78 in general payments during 2025 across 19 reported records.
Lundbeck LLC accounted for 43.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Rexulti, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $137.08 | 43.0% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $55.31 | 17.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $48.53 | 15.2% | 3 | 2025 |
| SPR Therapeutics, Inc | Unresolved — no canonical attribution shown | $35.91 | 11.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.13 | 6.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.82 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $318.78 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $185.61 | 13 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $55.31 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $55.31 | 3 | 2025 |
Source payment records
|
|||||
| SPRINT PNS System Normalized: sprint pns system |
Device | SPR Therapeutics, Inc | $35.91 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 141 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 37 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 73 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
73 | 18 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
37 | 14 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
37 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
141 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 683 | 174 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 374 | 120 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 348 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 272 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 247 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 246 | 84 |
| Famotidine | Famotidine | 207 | 73 |
| Lisinopril | Lisinopril | 206 | 54 |
| Telmisartan | Telmisartan | 205 | 50 |
| Quetiapine Fumarate | Quetiapine Fumarate | 196 | 58 |
| Bupropion Xl | Bupropion Hcl | 170 | 46 |
| Metformin Hcl Er | Metformin Hcl | 164 | 38 |
| Gabapentin | Gabapentin | 163 | 38 |
| Losartan Potassium | Losartan Potassium | 161 | 50 |
| Farxiga | Dapagliflozin Propanediol | 154 | 28 |
| Celecoxib | Celecoxib | 148 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 148 | 36 |
| Eliquis | Apixaban | 141 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 138 | 44 |
| Metformin Hcl | Metformin Hcl | 135 | 33 |
| Ozempic | Semaglutide | 129 | 26 |
| Furosemide | Furosemide | 114 | 35 |
| Omeprazole | Omeprazole | 108 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 106 | 19 |
| Carvedilol | Carvedilol | 105 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 34 |
| Rybelsus | Semaglutide | 101 | 21 |
| Simvastatin | Simvastatin | 101 | 26 |
| Jardiance | Empagliflozin | 100 | 31 |
| Trazodone Hcl | Trazodone Hcl | 99 | 29 |
| Chlorthalidone | Chlorthalidone | 96 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 27 |
| Linzess | Linaclotide | 76 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 18 |
| Valacyclovir | Valacyclovir Hcl | 73 | 20 |
| Potassium Chloride | Potassium Chloride | 72 | 23 |
| Nebivolol Hcl | Nebivolol Hcl | 71 | 19 |
| Naproxen | Naproxen | 70 | 41 |
| Montelukast Sodium | Montelukast Sodium | 69 | 22 |
| Myrbetriq | Mirabegron | 69 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 29 |
| Spironolactone | Spironolactone | 68 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 51 |
| Finasteride | Finasteride | 64 | 21 |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 64 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 62 | 14 |
| Alprazolam | Alprazolam | 61 | 14 |
| Donepezil Hcl | Donepezil Hcl | 60 | 14 |
| Trulicity | Dulaglutide | 58 | 14 |
| Alendronate Sodium | Alendronate Sodium | 53 | 12 |
| Atenolol | Atenolol | 51 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 12 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 51 | 13 |
| Pregabalin | Pregabalin | 50 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 24 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 44 | 11 |
| Memantine Hcl | Memantine Hcl | 42 | 12 |
| Vilazodone Hcl | Vilazodone Hcl | 42 | 14 |
| Baclofen | Baclofen | 41 | 16 |
| Meclizine Hcl | Meclizine Hcl | 41 | suppressed |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Progesterone | Progesterone, Micronized | 41 | suppressed |
| Allopurinol | Allopurinol | 40 | 11 |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Prednisone | Prednisone | 39 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 11 |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 12 |
| Rexulti | Brexpiprazole | 37 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 37 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | 14 |
| Nystatin | Nystatin | 36 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Sucralfate | Sucralfate | 36 | 15 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Irbesartan | Irbesartan | 35 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Ezetimibe | Ezetimibe | 34 | 11 |
| Meloxicam | Meloxicam | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 11 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | 11 |
| Terconazole | Terconazole | 25 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 24 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 20 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 21 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Lorazepam | Lorazepam | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 11 |
| Metronidazole | Metronidazole | 14 | 14 |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $318.78 · 19 records | Lundbeck LLC | Auvelity, ELIQUIS, NURTEC ODT, REXULTI, SPRINT PNS System, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error